Taspoglutide. GLP-1 analogue treatment of diabetes

Drugs of the Future

Volumn 33, Issue 11, 2008, Pages 938-943

  Arjona, A ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIM 51077; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ITM 077; METFORMIN; PLACEBO; R 1583; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ENZYME DEGRADATION; EXERCISE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; SIDE EFFECT; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 60549101688     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.011.1277240     Document Type: Article

References (24)

1. Leahy, J.L. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005, 36(3): 197-209.
2. 2007 National Diabetes Fact Sheet. US Centers for Disease Control and Prevention. CDC.gov Web site.
3. Pratley, R.E., Gilbert, M. Targeting incretins in type 2 diabetes: Role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008, 5(2): 73-94.
4. Drucker, D.J. The biology of incretin hormones. Cell Metab 2006, 3(3): 153-65.
5. Nauck, M., Stockmann, F., Ebert, R., Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29(1): 46-52.
6. Vilsbøll, T., Agersø, H., Krarup, T., Holst, J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88(1): 220-4.
7. Mizuno, C.S., Chittiboyina, A.G., Kurtz, T.W., Pershadsingh, H.A., Avery, M.A. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem, 2008 15(1): 61-74.
8. Kjems, L.L., Holst, J.J., Volund, A., Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52(2): 380-6.
9. Rachman, J., Barrow, B.A., Levy, J.C., Turner, R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40(2): 205-11.
10. Wargent, E., Nolan, A.L., Shen, Y. et al. Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogues. Diabetologia 2000, 43(Suppl. A): A137.
11. Dong, J.Z., Shen, Y., Zhang, J. et al. Design and synthesis of a novel GLP-1 analog, BIM-51077, which has significantly improved in vivo activity. 18th Am Peptide Soc Symp (July 19-23, Boston) 2003, Abst.
12. Wargent, E.T., Sennitt, M.V., Woon, C.W., Cawthorne, M.A. The DPP IV resistant GLP-1 analogue, BIM 51077, improves diabetic control in ZDF rats. 18th Int Diabetes Fed Cong (Aug 24-29, Paris) 203, Abst 482.
13. Ramis, J., Menargues, A., Allue, J.A., Peraire, C., Cordero, J.A., Cherifcheikh, R. Pharmacokinetic profile of a SRF formulation of BIM51077, a novel GLP-1 analog, in the beagle dog. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 547-P.
14. Kapitza, C., Heise, T., Klein, O. et al. BIM51077, a novel GLP-1 analog, showed linear PK and dose-response relationship over 7 days of treatment. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 2019-PO.
15. Kapitza, C., Heise, T., Klein, O. et al. BIM51077, a novel GLP-1 analog, achieves sustained improvement in blood glucose control over 28 days of treatment. 66th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 9-13, Washington, D.C.) 2006, Abst 500-P.
16. Kapitza, C., Klein, O., Obach, R., Birman, P., Jallet, K., Balena, R. Long acting human GLP-1 analogue R1583: Safety, pharmacokinetic and pharmacodynamic properties after a single administration in subjects with type 2 diabetes. Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 506-P.
17. Ratner, R., Nauck, M., Asnaghi, V., Berria, R., Cressier, R., Boldrin, M., Balena, R. Safety and tolerability of high doses of the long acting, human GLP-1 analogue R1583 in diabetic subjects treated with metformin: A double-blind, placebo-controlled phase 2 study. Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 10-OR.
18. Balena, R., Ratner, R., Berria, R., Asnaghi, V., Grant, R., Snaith, J., Boldrin, M. Nauck, M. Eight weeks of treatment with the long acting, human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study. Diabetes [68th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 6-10, San Francisco) 2008] 2008, 57(Suppl. 1): Abst 108-OR.
19. Berria, R., Gastaldelli, A., Nauck, M., Boldrin, M., Asnaghi, V., Balena, R. Eight weeks treatment with RI 583, a novel long-acting, human GLP-1 analogue improves beta cell function in metformin-treated diabetic subjects: A double-blind, placebo-controlled phase 2 study. Diabetologia [44th Annu Meet Eur Assoc Study Diabetes (EASD) (Sept 8-11, Rome) 2008] 2008, 51(Suppl. 1): Abst 871.
20. A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with diet and exercise (NCT00744926). ClinicalTrials.gov Web site, November 20, 2008.
21. A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone (NCT00744367). ClinicalTrials.gov Web site, November 20, 2008.
22. A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin (NCT00754988). ClinicalTrials.gov Web site, November 20, 2008.
23. A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naive type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea (NCT00755287). ClinicalTrials.gov Web site, November 20, 2008.
24. A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both (NCT00717457). ClinicalTrials.gov Web site, November 20, 2008.